I have worked in research from ‘the bench to the community’ and have been involved since 1993 in numerous research grants either as main investigator, co-investigator, biostatistician or named researcher. I have experience in the fields of public health, genetics, health economics, social research, environmental health, translational health research and clinical trials, among others, in both academic and industry settings. I have led research projects at the WHO and other international organizations whilst working in Asia, South Pacific, USA and Europe. I previously focused on modelling genetic effects and interactions affecting quantitative traits in family-based study designs. I have been involved in studies of different diseases including cancer, cardiovascular diseases, respiratory diseases, chronic kidney disease, HIV/AIDS and diabetes.
My current research interest includes the following:
- Modelling techniques that could be efficiently applied to answer questions on identification of disease states, treatment efficacy, treatment cost-effectiveness and disease prevention
- Applications of AI in biomarker studies, healthcare and clinical trials
- Population and family-based analysis methods in genetics
The following are my most recent research involvement:
FETONET: Evaluation of [18F]fluoroethyl triazole labelled [Tyr3]Octreotate analogues for the imaging of Neuroendocrine tumours (PI: Rohini Sharma, Imperial College London; 2018 – 2022)
RADICAL: A single arm phase IIa study (with combination safety run-in) to assess the safety and efficacy of AZD4547 in combination with either anastrozole or letrozole in ER positive breast cancer patients who have progressed on treatment with anastrozole or letrozole (PI: Michael Seckl, Imperial College London; 2018 – 2022)
ALERT: A phase II study of alternating eribulin and hormonal therapy in pre‐treated ER ve breast cancer (PI: Laura Kenny, Imperial College London; 2018 – 2020)
MICROBIOME: A first in human, phase 1 safety study in two parts to determine the safety, tolerability and anti-cancer immuno-modulatory effects of MRx0518 in patients with solid tumours awaiting surgical removal of the tumour (PI: Jonathan Krell, Imperial College London; 2018 – 2022)
HERPET: A mechanistic non-invasive imaging study of HER2 expression in breast cancer using [18F]GE-226 positron emission tomography. (PI: Laura Kenny, Imperial College London; 2018 – 2022)
CUPem: A Phase II, Two-Stage, Trial of Pembrolizumab in Cancer of unknown primary (PI: Harpreet Wasan, Imperial College London; 2018 – 2022)
READER-1: Re-irradiation with Arginine-Deprivation in patients with early-recurring Glioblastoma: A Phase 1 Trial (PI: Matthew Williams, Imperial College London; 2019 – 2022)
StarKap: Preliminary assessment of safety and tolerability of Dostarlimab in combination antiretroviral therapy (cART) refractory HIV associated Kaposi Sarcoma (PI: David Pinato, Imperial College London; 2021 – 2022)
PELICAN: A phase II study of etoposide-carboplatin (EP) chemotherapy in combination with pembrolizumab and lenvatinib maintenance in advanced high-grade neuroendocrine tumours (HG-NETs) (PI: David Pinato, Imperial College London; 2021 – 2022)
For a comprehensive list of my research projects and publications, please see: https://www.researchgate.net/profile/Jingky_Lozano-Kuehne
and ORCID iD: https://orcid.org/0000-0002-7372-0725
For a possible research collaboration, please contact me.
